SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
Europe - FRA:SRT3 - DE0007165631
224.5 EUR
+0.7 (+0.31%)
Taking everything into account, SRT3 scores 3 out of 10 in our fundamental rating. SRT3 was compared to 18 industry peers in the Life Sciences Tools & Services industry. SRT3 may be in some trouble as it scores bad on both profitability and health. SRT3 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRT3 had positive earnings in the past year.
SRT3 had a positive operating cash flow in the past year.
Each year in the past 5 years SRT3 has been profitable.
Each year in the past 5 years SRT3 had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.39%, SRT3 is doing worse than 83.33% of the companies in the same industry.
With a Return On Equity value of 5.01%, SRT3 is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
Looking at the Return On Invested Capital, with a value of 4.71%, SRT3 is doing worse than 77.78% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SRT3 is significantly below the industry average of 13.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.39% | ||
| ROE | 5.01% | ||
| ROIC | 4.71% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
With a Profit Margin value of 3.80%, SRT3 is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
In the last couple of years the Profit Margin of SRT3 has declined.
Looking at the Operating Margin, with a value of 14.06%, SRT3 is doing worse than 72.22% of the companies in the same industry.
In the last couple of years the Operating Margin of SRT3 has declined.
Looking at the Gross Margin, with a value of 46.48%, SRT3 is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
SRT3's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.06% | ||
| PM (TTM) | 3.8% | ||
| GM | 46.48% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SRT3 is creating some value.
Compared to 1 year ago, SRT3 has more shares outstanding
SRT3 has more shares outstanding than it did 5 years ago.
SRT3 has a better debt/assets ratio than last year.
2.2 Solvency
SRT3 has an Altman-Z score of 2.31. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
SRT3's Altman-Z score of 2.31 is on the low side compared to the rest of the industry. SRT3 is outperformed by 61.11% of its industry peers.
SRT3 has a debt to FCF ratio of 8.92. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.92 years to pay back of all of its debts.
The Debt to FCF ratio of SRT3 (8.92) is worse than 72.22% of its industry peers.
SRT3 has a Debt/Equity ratio of 1.28. This is a high value indicating a heavy dependency on external financing.
SRT3 has a worse Debt to Equity ratio (1.28) than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.28 | ||
| Debt/FCF | 8.92 | ||
| Altman-Z | 2.31 |
ROIC/WACC0.59
WACC7.96%
2.3 Liquidity
SRT3 has a Current Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.95, SRT3 is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
A Quick Ratio of 0.49 indicates that SRT3 may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.49, SRT3 is doing worse than 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 59.34% over the past year.
Measured over the past years, SRT3 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -11.87% on average per year.
The Revenue has been growing slightly by 5.82% in the past year.
The Revenue has been growing by 13.10% on average over the past years. This is quite good.
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%
3.2 Future
The Earnings Per Share is expected to grow by 19.28% on average over the next years. This is quite good.
SRT3 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.99% yearly.
EPS Next Y22.69%
EPS Next 2Y21.53%
EPS Next 3Y21.2%
EPS Next 5Y19.28%
Revenue Next Year5.43%
Revenue Next 2Y6.87%
Revenue Next 3Y8.23%
Revenue Next 5Y8.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 49.23 indicates a quite expensive valuation of SRT3.
Based on the Price/Earnings ratio, SRT3 is valued more expensive than 88.89% of the companies in the same industry.
When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (25.51), we can say SRT3 is valued expensively.
With a Price/Forward Earnings ratio of 37.09, SRT3 can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a rather expensive valuation: SRT3 more expensive than 83.33% of the companies listed in the same industry.
SRT3's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 34.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.23 | ||
| Fwd PE | 37.09 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as SRT3.
The rest of the industry has a similar Price/Free Cash Flow ratio as SRT3.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.12 | ||
| EV/EBITDA | 22.27 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SRT3 does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SRT3's earnings are expected to grow with 21.20% in the coming years.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y21.53%
EPS Next 3Y21.2%
5. Dividend
5.1 Amount
With a yearly dividend of 0.40%, SRT3 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.74, SRT3 has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.44, SRT3's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.4% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
37.92% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP37.92%
EPS Next 2Y21.53%
EPS Next 3Y21.2%
FRA:SRT3 (11/19/2025, 3:39:15 PM)
224.5
+0.7 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.81B
Revenue(TTM)3.52B
Net Income(TTM)133.70M
Analysts80
Price Target342.38 (52.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.4% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.71%
PT rev (3m)4.38%
EPS NQ rev (1m)3.45%
EPS NQ rev (3m)3.45%
EPS NY rev (1m)-0.47%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)2.71%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)-0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.23 | ||
| Fwd PE | 37.09 | ||
| P/S | 4.78 | ||
| P/FCF | 35.12 | ||
| P/OCF | 19.23 | ||
| P/B | 6.3 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.27 |
EPS(TTM)4.56
EY2.03%
EPS(NY)6.05
Fwd EY2.7%
FCF(TTM)6.39
FCFY2.85%
OCF(TTM)11.68
OCFY5.2%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)2.17
PEG (5Y)N/A
Graham Number60.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.39% | ||
| ROE | 5.01% | ||
| ROCE | 6.33% | ||
| ROIC | 4.71% | ||
| ROICexc | 4.98% | ||
| ROICexgc | 17.77% | ||
| OM | 14.06% | ||
| PM (TTM) | 3.8% | ||
| GM | 46.48% | ||
| FCFM | 13.61% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.28 | ||
| Debt/FCF | 8.92 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 92.32% | ||
| Cap/Sales | 11.25% | ||
| Interest Coverage | 2.65 | ||
| Cash Conversion | 94.72% | ||
| Profit Quality | 357.97% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.49 | ||
| Altman-Z | 2.31 |
F-Score7
WACC7.96%
ROIC/WACC0.59
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
EPS Next Y22.69%
EPS Next 2Y21.53%
EPS Next 3Y21.2%
EPS Next 5Y19.28%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%
Revenue Next Year5.43%
Revenue Next 2Y6.87%
Revenue Next 3Y8.23%
Revenue Next 5Y8.99%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year99.69%
EBIT Next 3Y38.21%
EBIT Next 5Y26.8%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%
SARTORIUS AG-VORZUG / SRT3.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.
What is the valuation status for SRT3 stock?
ChartMill assigns a valuation rating of 2 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS AG-VORZUG?
SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.
Can you provide the PE and PB ratios for SRT3 stock?
The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 49.23 and the Price/Book (PB) ratio is 6.3.
What is the expected EPS growth for SARTORIUS AG-VORZUG (SRT3.DE) stock?
The Earnings per Share (EPS) of SARTORIUS AG-VORZUG (SRT3.DE) is expected to grow by 22.69% in the next year.